MRKR (Marker Therapeutics) ROE % Adjusted to Book Value: -52.95% (As of Mar. 2026)


MRKR Marker Therapeutics Inc MRKR
30 GF Score
Price $1.68
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics ROE % Adjusted to Book Value?

Marker Therapeutics MRKR +13.51% 30 ROE % Adjusted to Book Value is -52.95% as of Mar. 2026. GuruFocus rates MRKR with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Marker Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -83.13%. Marker Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 1.57. Marker Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -52.95%.

Marker Therapeutics ROE % Adjusted to Book Value Related Terms

Marker Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics ROE % Adjusted to Book Value Chart

Marker Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.60 -82.58 -14.07 -36.77 -46.49

Marker Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -113.28 -77.94 -68.37 -26.16 -52.95

MRKR vs PLUR, VYNE, LGVN: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Marker Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's ROE % Adjusted to Book Value falls into.


MRKR
30GF Score
Marker Therapeutics Inc MRKR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics ROE % Adjusted to Book Value Calculation

Marker Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-68.81% / 1.48
=-46.49%

Marker Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-83.13% / 1.57
=-52.95%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -52.95% mean?
Marker Therapeutics (MRKR) has a ROE % Adjusted to Book Value of -52.95% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Marker Therapeutics and its competitors.
Is Marker Therapeutics' ROE % Adjusted to Book Value too high?
Marker Therapeutics' current ROE % Adjusted to Book Value is -52.95%. Overall, Marker Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' ROE % Adjusted to Book Value compare to PLUR and VYNE?
Marker Therapeutics' ROE % Adjusted to Book Value of -52.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Marker Therapeutics and its competitors. Marker Therapeutics's current ROE % Adjusted to Book Value is -52.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (MRKR) has a current ROE % Adjusted to Book Value of -52.95%. The current ROE % Adjusted to Book Value is -52.95%. Marker Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Marker Therapeutics (MRKR), the current ROE % Adjusted to Book Value is -52.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Other Exchanges GX1:Germany
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
30GF Score

Get the complete analysis for MRKR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.68
Price